Juel Carol, who serves as Executive Vice President and Chief Technology and Operating Officer at Synchrony Financial (NYSE:SYF), reported two related equity transactions at the beginning of March 2026 that are detailed in a Form 4 filing with the Securities and Exchange Commission.
On March 2, 2026, Carol sold 16,859 shares of Synchrony common stock at a price of $67.71 per share, generating proceeds of approximately $1.14 million. The filing also records that on March 1, 2026 Carol received a grant of 24,093 shares of Synchrony common stock with a total stated value of $1,665,067, priced at $69.11 per share. Those shares were issued as restricted stock units that will vest in three equal annual installments of 33.33% each, beginning on the first anniversary of the grant date.
According to the same filing, 14,561 shares were withheld to cover tax liabilities related to the grant. The withheld shares are valued at $1,006,310 using the grant price of $69.11. After accounting for the sale, the grant, and the tax withholding, Carol is listed as directly owning 51,446 shares of Synchrony Financial common stock.
Company snapshot and market context
The filings arrive against the backdrop of Synchrony’s broader financial profile: the company carries a market capitalization of $23.87 billion, trades at a reported price-to-earnings ratio of 7.47, and yields 1.75% via dividends. Analysis from InvestingPro cited in the filing commentary characterizes Synchrony as appearing undervalued at current levels and places the company on a Most Undervalued list. The InvestingPro note also indicates the service provides access to additional exclusive tips and financial metrics for deeper analysis.
Separately, Synchrony reported fourth-quarter 2025 net earnings of $751 million, or $2.04 per diluted share, which met earnings-per-share expectations. Revenue for the quarter totaled $3.79 billion, however, missing the $3.84 billion figure that analysts had anticipated. That revenue shortfall is specifically noted as a point of investor concern.
In the wake of the quarterly results, Baird upgraded its rating on Synchrony from Neutral to Outperform, citing solid pre-provision net revenue trends and favorable employment metrics as supportive elements for the change in view.
Strategic activity
Synchrony has continued to pursue strategic partnerships focused on healthcare and dental payments. The company announced an agreement with Weave to integrate CareCredit’s patient financing offering into Weave’s platform to streamline payment workflows for healthcare providers. In addition, Synchrony expanded a partnership with Planet DDS, naming CareCredit the preferred financing solution across dental practice management platforms and planning an integration into the orthodontic-specific Cloud 9 system. These initiatives are presented as efforts to broaden CareCredit’s distribution within clinical and dental practice software environments.
What the filings show
- Sale: 16,859 shares sold on March 2, 2026 at $67.71, proceeds approximately $1.14 million.
- Grant: 24,093 restricted stock units granted on March 1, 2026, total value $1,665,067 at $69.11 per share; vesting in three equal annual installments of 33.33%.
- Withholding: 14,561 shares withheld for taxes, valued at $1,006,310 at $69.11 per share.
- Post-transaction direct ownership: 51,446 shares.
The Form 4 filing provides the official record of these transactions; it does not include commentary on Carol’s motivations or on any intended future transactions beyond the stated vesting schedule for the restricted stock units.